Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Stanford University
Stanford University
Mayo Clinic
Essen Biotech
BriaCell Therapeutics Corporation
National Institutes of Health Clinical Center (CC)
The Netherlands Cancer Institute
Memorial Sloan Kettering Cancer Center
Hadassah Medical Organization
Acepodia Biotech, Inc.
ETOP IBCSG Partners Foundation
Capital Medical University
Leap Therapeutics, Inc.
Fred Hutchinson Cancer Center
The Netherlands Cancer Institute
Centre Leon Berard
National Institutes of Health Clinical Center (CC)
UMC Utrecht
National Institutes of Health Clinical Center (CC)
Merrimack Pharmaceuticals
HaEmek Medical Center, Israel
Rutgers, The State University of New Jersey
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)